Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F23%3A00009542" target="_blank" >RIV/00023884:_____/23:00009542 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/23:00133390 RIV/00216208:11130/23:10455101 RIV/00843989:_____/23:E0110120 RIV/00064203:_____/23:10455101 and 2 more

Result on the web

<a href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1014455/full" target="_blank" >https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1014455/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fonc.2022.1014455" target="_blank" >10.3389/fonc.2022.1014455</a>

Result language

angličtina

Original language name

Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma

Original language description

The prognosis of glioblastoma remains unfavorable. TTFields utilize low intensity electric fields (frequency 150–300 kHz) that disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields are delivered via transducer arrays placed on the patients’ scalp. Methods: Between the years 2004 and 2022, 55 patients (20 female), aged 21.9–77.8 years (mean age 47.3±11.8 years; median 47.6 years) were treated with TTFields for newly-diagnosed GBM, and compared to 54 control patients (20 females), aged 27.0–76.7 years (mean age 51.4±12.2 years; median 51.7 years) (p=0.08). All patients underwent gross total or partial resection of GBM. One patient had biopsy only. When available, MGMT promoter methylation status and IDH mutation was detected.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in Oncology

ISSN

2234-943X

e-ISSN

—

Volume of the periodical

12

Issue of the periodical within the volume

January

Country of publishing house

CH - SWITZERLAND

Number of pages

9

Pages from-to

—

UT code for WoS article

000923996600001

EID of the result in the Scopus database

2-s2.0-85147275259